HUE042839T2 - Piridilaminoecetsav vegyületek - Google Patents

Piridilaminoecetsav vegyületek

Info

Publication number
HUE042839T2
HUE042839T2 HUE09721163A HUE09721163A HUE042839T2 HU E042839 T2 HUE042839 T2 HU E042839T2 HU E09721163 A HUE09721163 A HU E09721163A HU E09721163 A HUE09721163 A HU E09721163A HU E042839 T2 HUE042839 T2 HU E042839T2
Authority
HU
Hungary
Prior art keywords
acid compound
pyridylaminoacetic acid
pyridylaminoacetic
compound
acid
Prior art date
Application number
HUE09721163A
Other languages
English (en)
Inventor
Ryo Iwamura
Masayuki Tanaka
Tetsushi Katsube
Manabu Shigetomi
Eiji Okanari
Yasunori Tokunaga
Hiroshi Fujiwara
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41065261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE042839(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ube Industries filed Critical Ube Industries
Publication of HUE042839T2 publication Critical patent/HUE042839T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
HUE09721163A 2008-03-12 2009-03-12 Piridilaminoecetsav vegyületek HUE042839T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008062926 2008-03-12

Publications (1)

Publication Number Publication Date
HUE042839T2 true HUE042839T2 (hu) 2019-07-29

Family

ID=41065261

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09721163A HUE042839T2 (hu) 2008-03-12 2009-03-12 Piridilaminoecetsav vegyületek

Country Status (18)

Country Link
US (2) US8648097B2 (hu)
EP (1) EP2264009B1 (hu)
JP (3) JP5136640B2 (hu)
KR (1) KR101609001B1 (hu)
CN (2) CN103965099A (hu)
AU (1) AU2009224329B2 (hu)
CA (1) CA2718393C (hu)
CY (1) CY1121543T1 (hu)
DK (1) DK2264009T3 (hu)
ES (1) ES2718813T3 (hu)
HR (1) HRP20190509T1 (hu)
HU (1) HUE042839T2 (hu)
LT (1) LT2264009T (hu)
PL (1) PL2264009T3 (hu)
PT (1) PT2264009T (hu)
SI (1) SI2264009T1 (hu)
TR (1) TR201904655T4 (hu)
WO (1) WO2009113600A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2264009T (pt) 2008-03-12 2019-04-29 Ube Industries Composto do ácido piridilaminoacético
PL2415763T3 (pl) * 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 N-置換ヘテロアリール化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
US20120184747A1 (en) * 2009-09-11 2012-07-19 Ube Industries, Ltd. Aniline compound
AU2010336248A1 (en) 2009-12-25 2012-08-02 Ube Industries, Ltd. Aminopyridine compound
AU2011225122B8 (en) 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
BR112012023551A2 (pt) 2010-03-18 2015-09-15 Bayer Ip Gmbh aril e hetaril sulfonamidas como agentes ativos contra estresse abiótico em plantas
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
TW201527282A (zh) * 2013-03-28 2015-07-16 Ube Industries 取代聯芳基化合物
CA2923016A1 (en) 2013-09-02 2015-03-05 Ube Industries, Ltd. Pharmaceutical composition for treatment and/or prevention of pulmonary disease
WO2015105134A1 (ja) 2014-01-10 2015-07-16 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
EP3093019B1 (en) * 2014-01-10 2021-05-26 Santen Pharmaceutical Co., Ltd Pharmaceutical composition containing pyridylamino acetic acid compound
CA2936026C (en) 2014-01-10 2022-04-19 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridylaminoacetic acid compound
JP6572890B2 (ja) * 2014-06-10 2019-09-11 宇部興産株式会社 ヘテロ芳香族スルホンアミド化合物の製造方法
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
WO2015190507A1 (ja) 2014-06-10 2015-12-17 宇部興産株式会社 N-置換スルホンアミド化合物およびその製造方法
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び/又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
US20180200239A1 (en) 2015-07-09 2018-07-19 Santen Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
WO2019025153A1 (de) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen
JP7250685B2 (ja) * 2017-09-29 2023-04-03 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
CN111491636A (zh) 2017-12-21 2020-08-04 参天制药株式会社 奥米帕格的组合
US11666563B2 (en) 2017-12-28 2023-06-06 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0532701A4 (en) 1990-06-08 1993-07-14 Sps Technologies, Inc. Improved magnetic materials and process for producing the same
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
CA2319198C (en) 1998-01-27 2011-02-22 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl factor xa inhibitors
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
AU2001297521B2 (en) 2001-10-26 2007-10-04 Allergan, Inc. Co-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
JP2005521668A (ja) 2002-01-31 2005-07-21 ファイザー・プロダクツ・インク (3−{[4−tert−ブチル−ベンジル)−(ピリジン−3−スルホニル)−アミノ]−メチル}−フェノキシ)−酢酸の代謝物
RU2306309C2 (ru) 2002-03-05 2007-09-20 Оно Фармасьютикал Ко., Лтд. Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
JP2006519250A (ja) 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるep2選択的受容体アゴニストの使用
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
WO2005072743A1 (ja) 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
JP2007186424A (ja) 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
EP1714961B1 (en) 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
WO2006009876A2 (en) 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
JP4966866B2 (ja) 2005-01-14 2012-07-04 エフ.ホフマン−ラ ロシュ アーゲー mGluR5アンタゴニストとしてのチアゾール−4−カルボキサミド誘導体
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
AU2006275263A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
EP1951701A2 (en) * 2005-08-09 2008-08-06 Asterand Uk Limited Ep2 receptor agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
UA94953C2 (en) * 2006-07-28 2011-06-25 Пфайзер Продактс Инк. Ep2 agonists
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
PT2264009T (pt) 2008-03-12 2019-04-29 Ube Industries Composto do ácido piridilaminoacético
PL2415763T3 (pl) 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry

Also Published As

Publication number Publication date
US20110054172A1 (en) 2011-03-03
EP2264009B1 (en) 2019-03-06
JP2013063994A (ja) 2013-04-11
EP2264009A4 (en) 2012-08-01
JP5545344B2 (ja) 2014-07-09
JP2014177476A (ja) 2014-09-25
CA2718393A1 (en) 2009-09-17
PL2264009T3 (pl) 2019-07-31
CN101970410A (zh) 2011-02-09
KR101609001B1 (ko) 2016-04-04
CY1121543T1 (el) 2020-05-29
DK2264009T3 (en) 2019-04-15
ES2718813T3 (es) 2019-07-04
AU2009224329A1 (en) 2009-09-17
US20140113907A1 (en) 2014-04-24
CA2718393C (en) 2015-06-16
HRP20190509T1 (hr) 2019-05-03
US8648097B2 (en) 2014-02-11
AU2009224329B2 (en) 2013-11-07
JP5136640B2 (ja) 2013-02-06
WO2009113600A1 (ja) 2009-09-17
EP2264009A1 (en) 2010-12-22
KR20100123903A (ko) 2010-11-25
PT2264009T (pt) 2019-04-29
JPWO2009113600A1 (ja) 2011-07-21
SI2264009T1 (sl) 2019-05-31
LT2264009T (lt) 2019-04-25
CN101970410B (zh) 2014-06-25
TR201904655T4 (tr) 2019-06-21
CN103965099A (zh) 2014-08-06

Similar Documents

Publication Publication Date Title
HRP20190509T1 (hr) Spoj piridilaminooctene kiseline
HK1153453A1 (en) Carboxylic acid compound
GB0818033D0 (en) Novel compound
HK1226051A1 (zh) 14-羥基-二十二烯酸化合物
SI2192109T1 (sl) Biciklični aminokislinski derivati
GB0800035D0 (en) Compounds
GB0804989D0 (en) Compound
ZA201000869B (en) Phenylacetic acid compound
EP2284159A4 (en) 5-hydroxypyrimidine-4-carboxamide compound
GB0803494D0 (en) Compound
IL206524A0 (en) 4-dimethylminobutyric acid derivatives
GB0800367D0 (en) Compounds
IL207035A0 (en) Benzylpiperizine compound
GB0823316D0 (en) Compound
GB0820918D0 (en) Compound
GB0805430D0 (en) Compound
GB0820919D0 (en) Compound
GB0820916D0 (en) Compound
GB0820915D0 (en) Compound
GB0806844D0 (en) Compound
GB0815806D0 (en) Compound
GB0802227D0 (en) Compound
GB0822635D0 (en) Compound
GB0806005D0 (en) Compound
GB0820249D0 (en) Compound